A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
Area of Focus
Immunology
Programs
IRAK4 (KT-474)
Development Stage
Pre-clinical Data
Share
